Live Attenuated Vaccines Market

Table of Content

1. INTRODUCTION
   1. Study Assumptions and Market Definition
   2. Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
   1. Market Overview
   2. Market Drivers
      1. Rising Prevalence of Infectious Diseases Worldwide
   3. Market Restraints
      1. Safety Concerns
      2. Storage and Transportation Challenges
   4. Market Opportunities
      1. Technological Advancements in Vaccine Development
   5. Market Trends
      1. Focus on Combination Vaccines
      2. Expansion in Emerging Markets
5. MARKET SEGMENTATION
   1. By Product Type
      1. Bacterial
      2. Viral
   2. By Development
      1. Tissue Culture
      2. Embryonated Eggs
      3. Live Animals
   3. By Indication
      1. Tuberculosis
      2. Measles
      3. Rotavirus
      4. Yellow Fever
      5. Oral Polio
      6. Others
   4. By Mode of Administration
      1. Oral
      2. Injectable
      3. Others
   5. By End User
      1. Hospitals
      2. Homecare
      3. Specialty Clinics
      4. Others
   6. By Distribution Channel
      1. Hospital Pharmacies
      2. Retail Pharmacies
      3. Online Pharmacies
   7. By Key Geographic Regions
      1. North America
         1. United States
         2. Canada
         3. Mexico
      2. Europe
         1. Germany
         2. United Kingdom
         3. France
         4. Italy
         5. Spain
         6. Rest of Europe
      3. Asia Pacific
         1. China
         2. Japan
         3. India
         4. Australia
         5. South Korea
         6. Rest of Asia Pacific
      4. Middle East and Africa
         1. GCC
         2. South Africa
         3. Rest of Middle East and Africa
      5. South America
         1. Brazil
         2. Argentina
         3. Rest of South America
6. COMPETITIVE LANDSCAPE
   1. Company Profile
      1. Astellas Pharma Inc. (Japan)
      2. CSL Limited (Australia)
      3. Emergent BioSolutions, Inc. (U.S.)
      4. GlaxoSmithKline, plc. (U.K.)
      5. Johnson & Johnson (U.S.)
      6. Merck & Co. (U.S.)
      7. MedImmune, LLC (U.S.)
      8. Pfizer, Inc. (U.S.)
      9. Sanofi (France)
      10. Serum Institute of India Pvt. Ltd. (India)
   2. MARKET OPPORTUNITIES AND FUTURE TRENDS

Frequently Asked Questions

Q.1. What is the projected market value of the global Live Attenuated Vaccinesmarket?

The global market of Live Attenuated Vaccines is projected to reach USD 60,396.59 Mn by 2033.

Q.2. What is the estimated growth rate (CAGR) of the global Live Attenuated Vaccines market?

The global Live Attenuated Vaccines market has an estimated annual growth rate of 12.3%. 

Q.3. What are the recent trends of Live Attenuated Vaccines market?

Focus on combination therapies and expansion in emerging marketsare some of the major trends of the market that is projected to boost the market growth in the near future.

Q.4. Which are the top companies to hold the market share in Live Attenuated Vaccines ?

The major companies profiled in this report include Astellas Pharma Inc. (Japan), CSL Limited (Australia), Emergent BioSolutions, Inc. (U.S.), GlaxoSmithKline, plc. (U.K.), Johnson & Johnson (U.S.), Merck & Co. (U.S.), MedImmune, LLC (U.S.), Pfizer, Inc. (U.S.), Sanofi (France), Serum Institute of India Pvt. Ltd. (India), among others.

Q.5. Which region is estimated to held highest CAGR inLive Attenuated Vaccinesmarket?

North America is estimated to hold biggest share in the market for Live Attenuated Vaccines.